12:00 AM
May 06, 2002
 |  BioCentury  |  Tools & Techniques

Targeting biological activity

One impact of genomics has been a shift in drug discovery from an emphasis on biological activity to an emphasis on targets. Perhaps the best example of this is in the antibiotic arena, where investigators have had microbial genomes mapped for a relatively long time, and have been busy ferreting out essential genes.

However, target-based discovery has yet to provide clinically useful antibiotics. So to increase the odds of success, researchers at Bristol-Myers Squibb Co. and GlaxoSmithKline plc are doing what needed to be done all along, merging biological activity with target-based discovery.

All marketed...

Read the full 466 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >